REACT-Genomics England (GE) [COVID-19]
Research type
Research Study
Full title
REACT-Genomics England (GE) sub-study (REACT-GE): Multi-omics to identify biological pathways underlying susceptibility to and severity of SARS-CoV-2 infection
IRAS ID
291775
Contact name
Paul Elliott
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
0 years, 9 months, 0 days
Research summary
This is a research study into the factors that determine why some people who contract COVID-19 suffer a milder condition or have no symptoms at all, whilst others suffer more severely requiring hospitalisation and even intensive care.
In this study, we will carry out an in-depth analysis of blood and urine samples donated by people who have tested positive for COVID-19 antibodies and have suffered milder symptoms which did not require hospitalisation or no symptoms at all. This study will focus on identifying links between the proteins and small molecules present in blood and urine, DNA and how genetic code is expressed in participants' body and how these affect susceptibility to and severity of COVID-19.
The overall purpose is to support the development of better treatments or vaccines for COVID-19.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
20/SC/0447
Date of REC Opinion
10 Dec 2020
REC opinion
Favourable Opinion